David Allsop

List of Publications by Year in Descending Order

97 papers	8,781 citations	42 h-index	93 g-index
104 ext. papers	9,798 ext. citations	6.9 avg, IF	5.66 L-index

#	Paper	IF	Citations
97	Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics. *PLoS ONE*, **2021**, 16, e0260323	3.7	4
96	Variation in the concentration and regional distribution of magnetic nanoparticles in human brains, with and without Alzheimer's disease, from the UK. *Scientific Reports*, **2021**, 11, 9363	4.9	5
95	Cerebral spinal fluid biomarker profiles in CNS infection associated with HSV and VZV mimic patterns in Alzheimer's disease. *Translational Neurodegeneration*, **2021**, 10, 2	10.3	0
94	Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens. *Journal of Clinical Medicine*, **2020**, 9,	5.1	12
93	Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis. *Journal of Neurology*, **2020**, 267, 214-227	5.5	11
92	Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients. *PLoS ONE*, **2019**, 14, e0211575	3.7	16
91	Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. *Annals of Clinical and Translational Neurology*, **2019**, 6, 2489-2502	5.3	22
90	Blood-based near-infrared spectroscopy for the rapid low-cost detection of Alzheimer's disease. *Analyst, The*, **2018**, 143, 5959-5964	5	18
89	Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood. *ACS Chemical Neuroscience*, **2018**, 9, 2786-2794	5.7	38
88	Liposome delivery systems for the treatment of Alzheimer's disease. *International Journal of Nanomedicine*, **2018**, 13, 8507-8522	7.3	70
87	Self-Assembly and Anti-Amyloid Cytotoxicity Activity of Amyloid beta Peptide Derivatives. *Scientific Reports*, **2017**, 7, 43637	4.9	29
86	Increased levels of plasma total tau in adult Down syndrome. *PLoS ONE*, **2017**, 12, e0188802	3.7	30
85	Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. *Molecular Neurodegeneration*, **2017**, 12, 63	19	140
84	Synuclein Interacts with Lipoproteins in Plasma. *Journal of Molecular Neuroscience*, **2017**, 63, 165-172	3.3	18
83	Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7929-E7938	11.5	79
82	Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes. *Interface Focus*, **2017**, 7, 20160127	3.9	16
81	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's A peptide. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2017**, 13, 723-732	6	39

80	A levels in the jugular vein and high molecular weight A oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. *PLoS ONE*, **2017**, 12, e0174630	2.7	7
79	Designed Glycopeptidomimetics Disrupt Protein-Protein Interactions Mediating Amyloid Peptide Aggregation and Restore Neuroblastoma Cell Viability. *Journal of Medicinal Chemistry*, **2016**, 59, 2025-40	8.3	25
78	Effects of different isoforms of apoE on aggregation of the synuclein protein implicated in Parkinson's disease. *Neuroscience Letters*, **2016**, 618, 146-151	3.3	21
77	Magnetite pollution nanoparticles in the human brain. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10797-801	11.5	516
76	Development & automation of a novel [(18)F]F prosthetic group, 2-[(18)F]-fluoro-3-pyridinecarboxaldehyde, and its application to an amino(oxy)-functionalised A peptide. *Applied Radiation and Isotopes*, **2016**, 116, 120-7	1.7	8
75	A preliminary electron microscopic investigation into the interaction between A 1-42peptide and a novel nanoliposome- coupled retro-inverso peptide inhibitor, developed as a potential treatment for Alzheimer's disease. *Journal of Physics: Conference Series*, **2015**, 644, 012040	0.3	4
74	Ultrasonic force microscopy for nanomechanical characterization of early and late-stage amyloid- peptide aggregation. *Scientific Reports*, **2014**, 4, 4004	4.9	18
73	amyloid fibrils in Alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species. *Journal of Biological Chemistry*, **2014**, 289, 12052-12062	5.4	75
72	Amyloid peptide and Alzheimer's disease. *Essays in Biochemistry*, **2014**, 56, 99-110	7.6	18
71	A longitudinal study on synuclein in blood plasma as a biomarker for Parkinson's disease. *Scientific Reports*, **2013**, 3, 2540	4.9	97
70	Correlation of A oligomer levels in matched cerebrospinal fluid and serum samples. *Neuroscience Letters*, **2013**, 551, 17-22	3.3	19
69	A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1E9 mouse model of Alzheimer's disease. *PLoS ONE*, **2013**, 8, e54769	3.7	65
68	Post mortem cerebrospinal fluid synuclein levels are raised in multiple system atrophy and distinguish this from the other synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. *Neurobiology of Disease*, **2012**, 45, 188-95	7.5	66
67	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for A oligomers. *Biochemical and Biophysical Research Communications*, **2012**, 422, 375-80	2.4	9
66	Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's A peptide. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2011**, 7, 541-50	6	98
65	The amylin peptide implicated in type 2 diabetes stimulates copper-mediated carbonyl group and ascorbate radical formation. *Free Radical Biology and Medicine*, **2011**, 51, 869-75	7.8	10
64	TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. *Acta Neuropathologica*, **2011**, 122, 703-13	14.3	106
63	Phosphorylated synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. *FASEB Journal*, **2011**, 25, 4127-37	0.9	146

62	Hypothesis: soluble a□oligomers in association with redox-active metal ions are the optimal generators of reactive oxygen species in Alzheimer's disease. *International Journal of Alzheimer's Disease*, **2010**, 2011, 546380	3.7	25
61	High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. *FASEB Journal*, **2010**, 24, 2716-26	0.9	196
60	Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. *Biochemistry*, **2010**, 49, 3261-72	3.2	120
59	Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *Acta Neuropathologica*, **2009**, 117, 55-62	14.3	148
58	Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. *Acta Neuropathologica*, **2009**, 118, 647-58	14.3	65
57	Galantamine inhibits beta-amyloid aggregation and cytotoxicity. *Journal of the Neurological Sciences*, **2009**, 280, 49-58	3.2	74
56	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. *Brain*, **2009**, 132, 1093-101	11.2	168
55	Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. *Biochemistry*, **2008**, 47, 1984-92	3.2	123
54	Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. *Biochemical Society Transactions*, **2008**, 36, 1293-8	5.1	69
53	TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. *Acta Neuropathologica*, **2008**, 116, 141-6	14.3	115
52	An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid. *Brain Research*, **2007**, 1170, 103-11	3.7	8
51	Copper-mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus?. *FEBS Letters*, **2007**, 581, 3489-93	3.8	70
50	Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. *Lancet Neurology, The*, **2006**, 5, 1000-1; author reply 1002-3	24.1	18
49	A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein. *Free Radical Research*, **2006**, 40, 731-9	4	15
48	Donepezil for severe Alzheimer's disease. *Lancet, The*, **2006**, 368, 361; author reply 362	40	2
47	Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. *FASEB Journal*, **2006**, 20, 419-25	0.9	541
46	Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. *Biochemical and Biophysical Research Communications*, **2006**, 349, 162-6	3.4	335
45	Protein aggregation, metals and oxidative stress in neurodegenerative diseases. *Biochemical Society Transactions*, **2005**, 33, 1082-1086	5.1	82

44	Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. *Journal of Biological Chemistry*, **2005**, 280, 35789-92	5.4	180
43	A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. *FASEB Journal*, **2004**, 18, 1315-7	0.9	146
42	Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. *Biochemistry*, **2004**, 43, 819-26	3.2	47
41	Induction of cellular oxidative stress by the beta-amyloid peptide involved in Alzheimer's disease. *Protein and Peptide Letters*, **2004**, 11, 257-70	1.9	3
40	Alpha-synuclein and the pathogenesis of Parkinson's disease. *Protein and Peptide Letters*, **2004**, 11, 229-37	1.9	22
39	Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. *NeuroReport*, **2003**, 14, 1743-5	1.7	29
38	Soluble oligomers for the diagnosis of neurodegenerative diseases. *Lancet Neurology, The*, **2003**, 2, 461-2	24.1	40
37	Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay. *Journal of Neurochemistry*, **2003**, 87, 620-30	6	36
36	Generation of hydrogen peroxide from mutant forms of the prion protein fragment PrP121-231. *Biochemistry*, **2003**, 42, 7675-81	3.2	42
35	Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. *FASEB Journal*, **2003**, 17, 1945-7	0.9	436
34	Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106-126. *Neuroscience Letters*, **2003**, 336, 159-62	3.3	62
33	Direct Production of Reactive Oxygen Species from Aggregating Proteins and Peptides Implicated in the Pathogenesis of Neurodegenerative Diseases. *Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents*, **2003**, 3, 299-308		7
32	Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. *Free Radical Biology and Medicine*, **2002**, 32, 1076-83	7.8	204
31	3-p-Toluoyl-2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran and 2-[4'-(3-diethylaminopropoxy)-phenyl]-benzofuran do not act as surfactants or micelles when inhibiting the aggregation of beta-amyloid peptide. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 255-7	2.9	32
30	New evidence that the Alzheimer beta-amyloid peptide does not spontaneously form free radicals: an ESR study using a series of spin-traps. *Free Radical Biology and Medicine*, **2001**, 30, 1154-62	7.8	46
29	alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. *Free Radical Biology and Medicine*, **2001**, 30, 1163-70	7.8	162
28	Fluorescence anisotropy: a method for early detection of Alzheimer beta-peptide (Abeta) aggregation. *Biochemical and Biophysical Research Communications*, **2001**, 285, 58-63	3.4	52
27	Modulation of beta-amyloid production and fibrillization. *Biochemical Society Symposia*, **2001**, 1-14		3

26	Characterization of peptidyl boronic acid inhibitors of mammalian 20S and 26S proteasomes and their inhibition of proteasomes in cultured cells. *Biochemical Journal*, **2000**, 346, 447	3.8	12
25	Pick's disease is associated with mutations in the tau gene. *Annals of Neurology*, **2000**, 48, 859-867	9.4	116
24	Introduction to Alzheimer's disease. *Methods in Molecular Medicine*, **2000**, 32, 1-21		1
23	A short synthesis of the amyloid (A) aggregation inhibitor 3-p-Toluoyl-2-[4?-(3-diethylaminopropoxy)-phenyl]-benzofuran. *Tetrahedron Letters*, **1999**, 40, 9383-9384	2	42
22	Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. *Nature Medicine*, **1997**, 3, 1016-20	50.5	649
21	Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. *Journal of Neurochemistry*, **1996**, 66, 740-7	6	94
20	The immunoreactive profile at the N-terminal region of A beta 1-39/40 but not A beta 1-42 changes with transition from monomer/dimer to further peptide aggregates. *Brain Research*, **1995**, 703, 237-241	3.7	13
19	Gerstmann-Str ssler-Scheinker disease showing beta-protein type cerebellar and cerebral amyloid angiopathy. *Acta Neuropathologica*, **1994**, 88, 262-6	14.3	11
18	Gelatinase A not alpha-secretase?. *Nature*, **1994**, 367, 27-8	50.4	16
17	Inflammatory mechanisms in Alzheimer's disease. *Trends in Pharmacological Sciences*, **1994**, 15, 447-50	13.2	203
16	Variability of beta-amyloid protein deposited lesions in Down's syndrome brains. *Tohoku Journal of Experimental Medicine*, **1994**, 174, 189-98	2.4	16
15	An investigation into the proteolytic cleavage of Alzheimer amyloid precursor protein in PC-12 cells. *Biochemical Society Transactions*, **1994**, 22, 14S	5.1	4
14	Aggregation of Alzheimer's peptides. *Biochemical Society Transactions*, **1994**, 22, 16S	5.1	
13	Amyloidosis in Alzheimer's disease. *Biochemical Society Transactions*, **1994**, 22, 171-5	5.1	3
12	Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. *Neuroscience Letters*, **1993**, 161, 17-20	3.3	86
11	Quantification of beta A4 protein deposition in the medial temporal lobe: a comparison of Alzheimer's disease and senile dementia of the Lewy body type. *Neuroscience Letters*, **1992**, 142, 9-12	3.3	27
10	Quantitative differences in the deposition of beta A4 protein in the sulci and gyri of frontal and temporal isocortex in Alzheimer's disease. *Neuroscience Letters*, **1992**, 136, 27-30	3.3	20
9	A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease. *Neuroscience Letters*, **1991**, 121, 271-3	3.3	13

8	Alzheimer amyloid beta/A4 peptide binding sites and a possible 'APP-secretase' activity associated with rat brain cortical membranes. *Brain Research*, **1991**, 551, 1-9	3.7	24
7	Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. *Brain Research*, **1991**, 548, 196-205	3.7	58
6	Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in Pharmacological Sciences*, **1991**, 12, 383-8	13.2	1710
5	The nomenclature of the cerebral amyloid fibril protein in Alzheimer's disease. *Neurobiology of Aging*, **1990**, 11, 63-4	5.6	
4	A possible unified nomenclature for Alzheimer amyloid protein, precursors and gene. *Neurobiology of Aging*, **1990**, 11, 69	5.6	1
3	Early senile plaques in Alzheimer's disease demonstrated by histochemistry, immunocytochemistry, and electron microscopy. *Human Pathology*, **1990**, 21, 1221-6	3.7	42
2	Demonstration of a 72 K protein precursor fragment in Alzheimer and normal aged brain . *Biomedical Research*, **1989**, 10, 179-183	1.5	15
1	Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer disease and other Tauopathies		1